[go: up one dir, main page]

WO2004108142A3 - Traitement d'etats lies au vieillissement - Google Patents

Traitement d'etats lies au vieillissement Download PDF

Info

Publication number
WO2004108142A3
WO2004108142A3 PCT/GB2004/002383 GB2004002383W WO2004108142A3 WO 2004108142 A3 WO2004108142 A3 WO 2004108142A3 GB 2004002383 W GB2004002383 W GB 2004002383W WO 2004108142 A3 WO2004108142 A3 WO 2004108142A3
Authority
WO
WIPO (PCT)
Prior art keywords
tip
treatment
cancer
tissue damage
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/002383
Other languages
English (en)
Other versions
WO2004108142A2 (fr
Inventor
Ian Hampson
Lynn Hampson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0313034A external-priority patent/GB0313034D0/en
Priority claimed from GB0322665A external-priority patent/GB0322665D0/en
Application filed by University of Manchester filed Critical University of Manchester
Publication of WO2004108142A2 publication Critical patent/WO2004108142A2/fr
Publication of WO2004108142A3 publication Critical patent/WO2004108142A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'agents permettant de réduire les niveaux cellulaires de la protéine-1 Tax (TIP-1) de HTLV1 ou d'inhiber ou modifier les effets fonctionnels de TlP-1 afin de traiter, prévenir ou limiter des dommages tissulaires. Ces agents sont particulièrement utiles pour prévenir un dommage pouvant apparaître comme résultat du processus de vieillissement et dans le traitement du cancer. L'invention concerne également le diagnostic et le traitement (y compris le traitement prophylactique) du cancer, et une méthode permettant d'identifier des cibles cancéreuses impliquées dans le processus d'invasion tumorale.
PCT/GB2004/002383 2003-06-06 2004-06-04 Traitement d'etats lies au vieillissement Ceased WO2004108142A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0313034.1 2003-06-06
GB0313034A GB0313034D0 (en) 2003-06-06 2003-06-06 Treatment amd diagnosis of cancer
GB0322665A GB0322665D0 (en) 2003-09-27 2003-09-27 Treatment and diagnosis of cancer
GB0322665.1 2003-09-27

Publications (2)

Publication Number Publication Date
WO2004108142A2 WO2004108142A2 (fr) 2004-12-16
WO2004108142A3 true WO2004108142A3 (fr) 2005-04-21

Family

ID=33512692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002383 Ceased WO2004108142A2 (fr) 2003-06-06 2004-06-04 Traitement d'etats lies au vieillissement

Country Status (1)

Country Link
WO (1) WO2004108142A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0723679D0 (en) * 2007-12-04 2008-01-16 Univ Manchester Prognostic marker for cancer
WO2015023110A1 (fr) * 2013-08-12 2015-02-19 사회복지법인 삼성생명공익재단 Biomarqueur pour le diagnostic d'une maladie tumorale et utilisation associée

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0956865A1 (fr) * 1996-08-12 1999-11-17 Yoshitomi Pharmaceutical Industries, Ltd. MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE
WO1999066946A1 (fr) * 1998-06-24 1999-12-29 Trustees Of The University Of Pennsylvania Compositions et procedes servant a provoquer une apoptose chez des cellules exprimant e6
WO2001015739A1 (fr) * 1999-08-31 2001-03-08 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression d'un gene humain de la famille rho
EP1177796A1 (fr) * 1999-04-27 2002-02-06 Mitsubishi Pharma Corporation Medicaments destines a soigner et a prevenir les maladies du foie
WO2003014303A2 (fr) * 2001-08-03 2003-02-20 Arbor Vita Corporation Interactions moleculaires dans les cellules
WO2004022541A1 (fr) * 2002-09-03 2004-03-18 Universite De Montreal Derives de cyclohexane 1,4-substitue
EP1452589A1 (fr) * 2003-02-28 2004-09-01 Migragen AG ADP-ribosyltransférase c3cer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0956865A1 (fr) * 1996-08-12 1999-11-17 Yoshitomi Pharmaceutical Industries, Ltd. MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE
WO1999066946A1 (fr) * 1998-06-24 1999-12-29 Trustees Of The University Of Pennsylvania Compositions et procedes servant a provoquer une apoptose chez des cellules exprimant e6
EP1177796A1 (fr) * 1999-04-27 2002-02-06 Mitsubishi Pharma Corporation Medicaments destines a soigner et a prevenir les maladies du foie
WO2001015739A1 (fr) * 1999-08-31 2001-03-08 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression d'un gene humain de la famille rho
WO2003014303A2 (fr) * 2001-08-03 2003-02-20 Arbor Vita Corporation Interactions moleculaires dans les cellules
WO2004022541A1 (fr) * 2002-09-03 2004-03-18 Universite De Montreal Derives de cyclohexane 1,4-substitue
EP1452589A1 (fr) * 2003-02-28 2004-09-01 Migragen AG ADP-ribosyltransférase c3cer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, 1 January 1900, Philadelphia, PA, US; abstract no. PREV199598550556, HOFMANN-WELLENHOF R, ET AL: "CORRELATION OF MELANOMA CELL MOTILITY AND INVASION IN VITRO" XP002296889 *
DATABASE biosis 1 January 1900 (1900-01-01), XP002296890, Database accession no. PREV199800264912 *
FILATOV L. ET AL.: "Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts expressing human papilloma virus type 16 E6 oncoprotein.", ONCOGENE, vol. 16, 1998, pages 1825 - 1838, XP002296888 *
REYNAUD C. ET AL.: "The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is involved in Rho signaling to the serum response element.", J.BIOL. CHEM., vol. 275, no. 43, 27 October 2000 (2000-10-27), pages 33962 - 22968, XP002296886 *
RIENTO K. AND RIDLEY A.: "ROCKs : multifunctional kinases in cell behaviour.", NATURE REVIEWS MOLECULAR CELL BIOLOGY., vol. 4, no. 6, June 2003 (2003-06-01), pages 446 - 456, XP009036656 *
SAWADA K. ET AL.: "Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells.", GYNECOLOGIC ONCOLOGY, vol. 87, 2002, pages 252 - 259, XP002313601 *
SOMLYO A V ET AL: "Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 269, no. 3, 24 March 2000 (2000-03-24), pages 652 - 659, XP002277882, ISSN: 0006-291X *
VAN AELST L. AND SYMONS M.: "Role of Rho family GTPases in epithelial morphogenesis.", GENES AND DEVELOPMENT, vol. 16, 2002, pages 1032 - 1054, XP002296887 *

Also Published As

Publication number Publication date
WO2004108142A2 (fr) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2006042249A3 (fr) Methodes et compositions de traitement de la douleur de migraine
WO2003049678A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2003050064A3 (fr) Inhibiteurs de kinesine mitotique
WO2003049527A3 (fr) Inhibiteurs miotitiques de la kinesine
WO2003050122A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2004030625A3 (fr) Procedes synergiques et compositions pour traiter le cancer
WO2005000213A8 (fr) Methode permettant de traiter des maladies a l'aide d'agent d'inhibition hsp90 combines a des inhibiteurs d'enzymes
WO2006135915A3 (fr) Methodes et compositions de traitement de maladies osseuses degeneratives
WO2004039774A3 (fr) Inhibiteurs de kinesine mitotique
SI1556083T1 (sl) Postopki za zdravljenje postoperativne bolečine z dajanjem protitelesa proti živčnemu rastnemu faktorju in sestavki, ki ga vsebujejo
WO2005018677A3 (fr) Utilisation d'un melange d'un inhibiteur de la kinase du recepteur de facteur de croissance epidermique et d'agents cytotoxiques dans le traitement et l'inhibition de cancer
WO2003079973A3 (fr) Inhibiteurs de kinesine mitotique
AU2001275228A1 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
WO2006024018A3 (fr) Methodes et compositions pour le traitement de la douleur nociceptive
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
WO2005060536A3 (fr) Technique de silençage genique mediee par si-rna en vue d'inhiber la tyrosinase et reduire la pigmentation
WO2003013554A3 (fr) Inhibiteurs de l'aromatase provenant de broussonetia papyrifera
WO2002096420A3 (fr) Procede de traitement d'accidents nerveux entraines par une operation
GB0221539D0 (en) Methods of treatment
WO2005060960A3 (fr) Utilisation de l'histamine pour le traitement de maladies osseuses
WO2005110479A3 (fr) Traitements pour le cancer
WO2006086693A3 (fr) Dispositifs medicaux
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
WO2004108142A3 (fr) Traitement d'etats lies au vieillissement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application